SCHEMBL7283173

SCHEMBL7283173

O=C(Nc1ccc([N+](=O)[O-])cc1)c1ccccc1Br

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.69
SMN1; SMN2 Q16637 6/20 0.69
NPC1 O15118 4/20 0.69
RAB9A P51151 4/20 0.69
ALDH1A1 P00352 4/20 0.67
CYP3A4 P08684 2/20 0.67
CYP2D6 P10635 2/20 0.67
CYP2C9 P11712 2/20 0.67
CYP2C19 P33261 2/20 0.67
HPGD P15428 1/20 0.67
HTT P42858 1/20 0.64
RXFP1 Q9HBX9 1/20 0.64
KMT2A Q03164 6/20 0.63
MEN1 O00255 5/20 0.63
POLB P06746 3/20 0.63
MITF O75030 1/20 0.63
ABCG2 Q9UNQ0 1/20 0.55
LMNA P02545 1/20 0.55
TP53 P04637 1/20 0.55
CYP1A2 P05177 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28659193 0.85 ALDH1A1 (0.71) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL874268 0.84 KMT2A (0.67) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL10519516 0.84 MAPT (0.68) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL2702303 0.83 NPC1 (0.71) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL7821134 0.83 MAPT (0.71) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL5079427 0.82 MAPT (0.71) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL25063320 0.82 MAPT (0.69) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL30981025 0.82 NPC1 (1.00) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL29168852 0.82 MAPT (0.69) MAPTSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL30338901 0.82 MAPT (0.69) MAPTSMN1; SMN2NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0516392-B1 Naphthyridine derivatives as angiotensin II inhibitors ASTRAZENECA AB (SE) 2001-08-29 EP disclosed
US-5420292-A Biphenyl-tetrazole intermediate compounds ZENECA LIMITED (GB) 1995-05-30 US disclosed
US-5334718-A Decyclizing a phenyl or a pyridyl or pyrimidyl group by reacting with a base to get angiotension antagonist ZENECA LIMITED (GB) 1994-08-02 US disclosed
US-5294716-A Chemical process for making angiotesin II antagonist compounds IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1994-03-15 US disclosed
US-5294620-A Hypotensive agents or compounds for cardiovascular disorders IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1994-03-15 US disclosed
US-5245035-A HETEROCYCLIC BORON COMPOUNDS AS INTERMEDIATES FOR ANGIOTENSIN II ANTAGONISTS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-09-14 US disclosed
US-5236937-A Treating hypertension, congestive heart failure IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-08-17 US disclosed
EP-0554098-A2 Process for the preparation of imidazo 4,5-b pyridine derivatives ZENECA LIMITED (GB) 1993-08-04 EP disclosed
CN-1073174-A Hete rocyclic derivatives ICI PLC (GB) 1993-06-16 CN disclosed
US-5217976-A Hypotensive agents, congestive heart failure IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-06-08 US disclosed
US-5198439-A Hypotensive agents, congestive heart failure IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-03-30 US disclosed
EP-0516392-A2 Naphthyridine derivatives as angiotensin II inhibitors ZENECA LIMITED (GB) 1992-12-02 EP disclosed
EP-0499415-A1 Pyridine and quinoline derivatives, processes for their manufacture and their use as angiotensin II antagonists ZENECA LIMITED (GB) 1992-08-19 EP disclosed
EP-0495626-A1 Process for the preparation of tetrazole derivatives ZENECA LIMITED (GB) 1992-07-22 EP disclosed
EP-0495627-A1 Boron compounds ZENECA LIMITED (GB) 1992-07-22 EP disclosed
US-5130318-A Hypotensive agents and for treatment of congestive heart failure IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-07-14 US disclosed